[Use of remaxol in the combination therapy of post-withdrawal disorders in alcoholic patients with comorbid liver damage].

Aim: To evaluate the efficacy of Remaxol used to treat post-withdrawal disorders in alcoholic patients with comorbid liver damage.

Subjects And Methods: The authors assessed the severity of clinical parameters, such as pathological craving and anhedonia, biochemical parameters (bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) in 120 patients aged 30-60 years in the stage of remission formation. The patients were divided into two groups: 1) 62 patients received Remaxol; 2) 58 persons took placebo (a comparative group).

[The role of reamberin in combined therapy of abstinence syndrome in alcoholics].

Clinical efficacy of 7 day reamberin therapy of abstinence syndrome was compared in 32 alcoholics with concomitant exogenous organic brain lesions (F 10.2, mean age 41.2 +/- 6.

Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission.

An open comparative clinical study evaluated the efficiency of Proproten-100 in reliving affective, somatovegetative, behavioral, and cognitive post-withdrawal disorders and manifestations of primary pathological alcohol addiction in patients with alcohol dependence in the stage of therapeutic remission. We compared the efficiency of Proproten-100 and standard symptomatic drugs. The preparation possessed anxiolytic, antidepressant, and vegetostabilizing properties, produced a moderate soporific effect, and had no sedative activity in patients with dysphoric depressions and psychopathic disorders.